ZyVersa Therapeutics Ownership
| ZVSADelisted Stock | 0.15 0.01 6.25% |
ZyVersa |
ZyVersa Stock Ownership Analysis
The company has Price to Book (P/B) ratio of 0.09. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. ZyVersa Therapeutics recorded a loss per share of 4.68. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 26th of April 2024. For more information please call the company at (754) 231-1688 or visit https://www.zyversa.com.ZyVersa Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ZyVersa Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ZyVersa Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ZyVersa Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ZyVersa Therapeutics Outstanding Bonds
ZyVersa Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ZyVersa Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ZyVersa bonds can be classified according to their maturity, which is the date when ZyVersa Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US98981BAA08 Corp BondUS98981BAA08 | View | |
| US98980BAA17 Corp BondUS98980BAA17 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in ZyVersa Stock
If you are still planning to invest in ZyVersa Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ZyVersa Therapeutics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |